Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2009. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting of share awards made in 2006 under the GlaxoSmithKline Performance Share Plan (PSP). The three-year performance period for these awards concluded on December 31, 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting equity compensation outcomes and does not contain financial statements or operational metrics.
Material Changes and Performance Outcomes
The Remuneration Committee determined the vesting status of 2006 PSP awards based on Total Shareholder Return (TSR) and Earnings Per Share (EPS) performance:
- Executive Directors and CET Members: Awards were dependent solely on TSR performance. These awards lapsed in full because GSK's relative TSR performance was below the median of the comparator group.
- Other Senior Executives: Awards were dependent on both TSR and EPS. Half of these awards lapsed due to TSR performance being below the median, while the other half vested because EPS performance exceeded the target level for full vesting.
Management Commentary and Unusual Items
Management commentary is limited to the specific determination of the Remuneration Committee regarding the 2006 PSP awards. The filing notes that the Company, Directors, and PDMRs were advised of these transactions on February 19, 2009. No guidance, outlook, risks, or contingencies regarding the company's broader business operations are included in this specific filing.
Important Facts for Investor Verification
- Executive Directors and CET members received zero shares from their 2006 PSP awards due to underperformance in TSR relative to peers.
- Senior executives received partial vesting (50%) of their 2006 awards, driven by EPS targets being met despite TSR underperformance.
- Specific share counts for lapsed and vested awards are detailed for named individuals, including Executive Directors A.P. Witty, J.S. Heslop, and M.M. Slaoui.
- This filing contains no financial data; investors must refer to other reports (e.g., Form 20-F or interim results) for revenue and profit figures.